Comparison of gene expression in HCT116 treatment derivatives generated by two different 5-fluorouracil exposure protocols
暂无分享,去创建一个
W. Reichelt | Terje Haug | Katherine L Kravik | Siv H Tunheim | Paula M De Angelis | Wenche H Reichelt | S. H. Tunheim | P. D. De Angelis | K. Kravik | T. Haug | S. Tunheim
[1] Z. Darżynkiewicz,et al. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. , 1993, Cancer research.
[2] D. Hedley,et al. The death-promoting activity of p53 can be inhibited by distinct signaling pathways. , 2002, Blood.
[3] J. Darnell,et al. Stat3 as an Oncogene , 1999, Cell.
[4] M. Jaroszeski,et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. , 1999, Cancer research.
[5] O. Legrand,et al. JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia. , 2001, Blood.
[6] J. Darnell,et al. The role of STATs in transcriptional control and their impact on cellular function , 2000, Oncogene.
[7] C. Boland,et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. , 1999, Gastroenterology.
[8] David G. Kirsch,et al. Caspase-3-dependent Cleavage of Bcl-2 Promotes Release of Cytochrome c * , 1999, The Journal of Biological Chemistry.
[9] J. Grandis,et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. , 1998, The Journal of clinical investigation.
[10] P. Johnston,et al. 5-Fluorouracil: mechanisms of action and clinical strategies , 2003, Nature Reviews Cancer.
[11] A. Mathur,et al. Evaluation of fluorescent dyes for the detection of mitochondrial membrane potential changes in cultured cardiomyocytes. , 2000, Cardiovascular research.
[12] Taylor Murray,et al. Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.
[13] A. Gao,et al. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. , 2000, Cancer research.
[14] R. Handschumacher,et al. Effect of clinically modeled regimens on the growth response and development of resistance in human colon carcinoma cell lines. , 1995, Biochemical pharmacology.
[15] B. Barton,et al. IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells , 2001, BMC Cancer.
[16] B. Dörken,et al. Paclitaxel-induced apoptosis in BJAB cells proceeds via a death receptor-independent, caspases-3/-8-driven mitochondrial amplification loop , 2003, Oncogene.
[17] J. Turkson,et al. Activation of Stat3 in v-Src-transformed Fibroblasts Requires Cooperation of Jak1 Kinase Activity* , 2000, The Journal of Biological Chemistry.
[18] E. Klein,et al. Hormonal therapy for prostate cancer: primum non nocere. , 2002, Urology.
[19] C. Allegra,et al. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. , 1995, Biochemical pharmacology.
[20] A. Goel,et al. Role of hMLH1 promoter hypermethylation in drug resistance to 5‐fluorouracil in colorectal cancer cell lines , 2003, International journal of cancer.
[21] R. Jove,et al. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. , 2001, Cancer research.
[22] M. Gleave,et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] J. Isaacs,et al. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer , 1996, The Prostate.
[24] M. Hawn,et al. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint. , 1995, Cancer research.
[25] F. Berger,et al. Functional effects of a naturally occurring amino acid substitution in human thymidylate synthase. , 1993, Molecular pharmacology.
[26] R. Oyasu,et al. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. , 1997, Cancer research.
[27] I. Pastan,et al. Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. , 1994, The Journal of urology.
[28] G. Peters,et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. , 2002, Biochimica et biophysica acta.
[29] S. Groshen,et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] F. Berger,et al. A naturally occurring variation in thymidylate synthase structure is associated with a reduced response to 5-fluoro-2'-deoxyuridine in a human colon tumor cell line. , 1988, Molecular pharmacology.
[31] M. David,et al. Distinct mechanisms of STAT phosphorylation via the interferon-alpha/beta receptor. Selective inhibition of STAT3 and STAT5 by piceatannol. , 2000, The Journal of biological chemistry.
[32] H. Fuse,et al. Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells. , 2001, Biochemical and biophysical research communications.
[33] Y. Geng,et al. Specific protection against breast cancers by cyclin D1 ablation , 2001, Nature.
[34] J. Turkson,et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.
[35] Takeshi Tokuhisa,et al. Activation of STAT3 by the Hepatitis C Virus Core Protein Leads to Cellular Transformation , 2002, The Journal of experimental medicine.
[36] Simon C Watkins,et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[37] J. Karras,et al. STAT3 regulates the growth and immunoglobulin production of BCL(1) B cell lymphoma through control of cell cycle progression. , 2000, Cellular immunology.
[38] P. Lamb,et al. Pharmaceutical intervention in the JAK/STAT signaling pathway , 2000, Oncogene.
[39] Trond Stokke,et al. Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil. , 2004, International journal of oncology.
[40] I Lebedeva,et al. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. , 2000, Cancer research.
[41] K Imada,et al. The Jak-STAT pathway. , 2000, Molecular immunology.
[42] J. Pow-Sang,et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. , 2002, Cancer research.
[43] M. Marcelli,et al. Overexpression of BCL-XL Underlies the Molecular Basis for Resistance to Staurosporine-induced Apoptosis in PC-3 Cells , 2001 .
[44] M. Meyers,et al. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. , 2001, Cancer research.
[45] A. Elefanty,et al. Comparison of effects of the tyrosine kinase inhibitors AG957, AG490, and STI571 on BCR-ABL--expressing cells, demonstrating synergy between AG490 and STI571. , 2001, Blood.
[46] J. Carethers,et al. Mutations of transforming growth factor beta 1 type II receptor, BAX, and insulin-like growth factor II receptor genes in microsatellite unstable cell lines. , 2000, In vivo.
[47] G. Kruh. Introduction to resistance to anticancer agents , 2003, Oncogene.
[48] J. Simons,et al. Interleukin-6: a candidate mediator of human prostate cancer morbidity. , 1995, Urology.
[49] L. Milas,et al. Enhancement of radiotherapy by oleandrin is a caspase-3 dependent process. , 2002, Cancer letters.
[50] P. Johnston,et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. , 1995, Cancer research.
[51] J. Simons,et al. Characterization of the role of IL‐6 in the progression of prostate cancer , 1999, The Prostate.
[52] H Kishi,et al. Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells. , 2000, Biochemical and biophysical research communications.
[53] L. Ellis,et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis , 2002, Oncogene.
[54] T. Savarese,et al. Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. , 2001, The American journal of pathology.
[55] B. Bonavida,et al. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[56] R. Jove,et al. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[57] J. Turkson,et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. , 2001, The Journal of clinical investigation.
[58] S. Beaucage,et al. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells. , 2001, Molecular pharmacology.
[59] M. Gleave,et al. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer. , 2001, Urology.
[60] J. Lammers,et al. STAT3β, a Splice Variant of Transcription Factor STAT3, Is a Dominant Negative Regulator of Transcription* , 1996, The Journal of Biological Chemistry.
[61] P. Johnston,et al. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. , 1992, Cancer research.
[62] M. Masuda,et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. , 2002, Cancer research.
[63] W. Farrar,et al. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. , 2000, Cancer research.
[64] J. Ihle,et al. STATs and MAPKs: obligate or opportunistic partners in signaling. , 1996, BioEssays : news and reviews in molecular, cellular and developmental biology.
[65] D. Tweardy,et al. Interleukin‐6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway , 2000, The Prostate.
[66] R. Lothe,et al. Apoptosis and expression of Bax, Bcl-x, and Bcl-2 apoptotic regulatory proteins in colorectal carcinomas, and association with p53 genotype/phenotype. , 1998, Molecular Pathology.
[67] J. Grandis,et al. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. , 2002, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[68] S. Kaye,et al. Drug resistance reversal--are we getting closer? , 2003, European journal of cancer.
[69] A. Belldegrun,et al. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. , 1995, Cancer research.
[70] J. Nelson,et al. Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice , 2002, The Prostate.